A Phase II Study of Safety and Efficacy of Camrelizumab, Apatinib combined with Radiotherapy for Advanced Non-clear Cell Renal Cell Carcinoma
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting, according to a results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 31 Jul 2020 New trial record